Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Status: No longer recruiting

Protocol number: NO16968

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of intermittent Xeloda in combination with Eloxatin, versus fluorouracil/leucovorin, on disease-free survival in patients who have undergone surgery for colon cancer.2

Brief summary: This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals. Target sample size is 1886.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Colorectal Cancer

Intervention type: Drug

Intervention name: capecitabine [Xeloda]

Primary outcome: 1. Superiority in disease-free survival Time frame: Event driven

Key secondary outcomes: 1. Adverse events, laboratory parameters. Time frame: Throughout study

Inclusion criteria:

  • adult patients >=18 years of age;
  • colon cancer;
  • complete tumor resection.

Exclusion criteria:

  • prior treatment with cytotoxic chemotherapy, radiotherapy, or immunotherapy for the currently treated colon cancer.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: April, 2003

Trial registration date: 06/24/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Australia

  • Adelaide
  • Melbourne
  • Perth
  • Port Macquarie
  • Sydney
  • Wollongong

Belgium

  • Bruxelles
  • Charleroi
  • Gent
  • Kortrijk
  • Leuven

Brazil

  • Belo Horizonte
  • Jaú
  • Sao Paulo

Canada

  • Calgary, AB
  • Edmonton, AB
  • Kelowna, BC
  • Surrey, BC
  • Victoria, BC
  • Winnipeg, MB
  • St John'S
  • Halifax, NS
  • Hamilton, ON
  • London, ON
  • Mississauga, ON
  • Oshawa, ON
  • Ottawa, ON
  • Toronto, ON
  • Weston, ON
  • Laval, QC
  • Levis, QC
  • Montreal, QC
  • Quebec City, QC

China

  • Beijing
  • Guangdong
  • Hangzhou
  • Hong Kong
  • Jiangsu
  • Jiangxi
  • Shanghai
  • Tianjin
  • Wuhan

Finland

  • Tampere
  • Turku

France

  • Colmar
  • Lille
  • Marseille
  • Strasbourg

Germany

  • Freiburg
  • Halle
  • Magdeburg
  • Trier

Greece

  • Athens
  • Heraklion
  • Patras
  • Thessaloniki

Hungary

  • Budapest
  • Debrecen
  • Szeged

Ireland

  • Cork
  • Dublin
  • Galway

Israel

  • Beer Sheva
  • Haifa
  • Jerusalem
  • Kfar Saba
  • Nahariya
  • Petah Tikva
  • Ramat Gan
  • Rehovot
  • Tel Aviv
  • Zerifin

Italy

  • Ancona
  • Bergamo
  • Cattolica
  • Genova
  • Livorno
  • Milano
  • Parma
  • Rimini
  • Sassari
  • Siena
  • Udine

Korea, Republic of

  • Seoul

Mexico

  • Chihuahua
  • Mexicali
  • Mexico City

New Zealand

  • Auckland
  • Christchurch
  • Dunedin
  • Palmerston North
  • Wellington

Panama

  • Panama City

Poland

  • Krakow
  • Lodz
  • Poznan
  • Szczecin
  • Warszawa
  • Zielona Gora

Portugal

  • Beja
  • Lisboa
  • Porto

Russian Federation

  • Moscow
  • St Petersburg

Singapore

  • Singapore

South Africa

  • Cape Town
  • Durban
  • Pietermaritzburg
  • Pretoria
  • Sandton

Spain

  • Barakaldo
  • Barcelona
  • Córdoba
  • Elche
  • Jaen
  • Leganes
  • Madrid
  • Malaga
  • Palma de Mallorca
  • Santander
  • Valencia

Switzerland

  • Basel

Taiwan

  • Kueishan
  • Taipei

Thailand

  • Bangkok
  • Khon Kaen

United Kingdom

  • Aberdeen
  • Belfast
  • Brighton
  • Bury St Edmunds
  • Cambridge
  • Denbigh
  • Derby
  • Glasgow
  • Guildford
  • Leeds
  • Leicester
  • London
  • Maidstone
  • Manchester
  • Middlesborough
  • Newcastle upon Tyne
  • Northwood
  • Nottingham
  • Plymouth
  • Salisbury
  • Southampton
  • Sutton

United States

  • Mobile, AL
  • Alhambra, CA
  • Bakersfield, CA
  • Fullerton, CA
  • Long Beach, CA
  • Los Angeles, CA
  • Northridge, CA
  • Oxnard, CA
  • Pomona, CA
  • Sacramento, CA
  • San Diego , CA
  • Santa Barbara, CA
  • Vista, CA
  • Denver, CO
  • Fort Collins, CO
  • Stamford, CT
  • Washington, DC
  • Lakeland, FL
  • Miami, FL
  • Atlanta, GA
  • Peoria, IL
  • Terre Haute, IN
  • New Orleans, LA
  • St Louis Park, MN
  • St Joseph, MO
  • St Louis, MO
  • Billings, MT
  • Reno , NV
  • Hooksett, NH
  • Morristown, NJ
  • Summit, NJ
  • Albuquerque, NM
  • New York, NY
  • Charlotte, NC
  • Greensboro, NC
  • Hickory , NC
  • Bethlehem, PA
  • Kingston , PA
  • Philadelphia, PA
  • Pittsburgh, PA
  • Memphis , TN
  • Fort Worth, TX
  • Salt Lake City, UT
  • Yakima, WA
  • Madison, WI

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply